Is Thermo Fisher Scientific, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Thermo Fisher Scientific, Inc. moved from expensive to fair. Based on the current metrics, the company appears fairly valued. Key valuation ratios include a P/E ratio of 26, an EV to EBITDA ratio of 18.39, and a Price to Book Value of 3.44. In comparison to peers, Abbott Laboratories has a P/E of 18.36, while Intuitive Surgical, Inc. shows a much higher P/E of 63.32, indicating that Thermo Fisher's valuation is more reasonable within its industry context.
In terms of recent performance, Thermo Fisher's stock returned 2.69% over the past week, outperforming the S&P 500's return of 1.70% during the same period. However, over the past year, the company has underperformed with a return of -10.07% compared to the S&P 500's 14.08%. Overall, while the stock has shown some short-term strength, its longer-term performance relative to the benchmark suggests caution.